> The trial involved about 5,300 women and female adolescents ages 16 to 25 in South Africa and Uganda, some of whom who received Gilead lenacapavir, and others who received older once-daily drugs from Gilead, including Truvada or Descovy.
Not to mention a superficial understanding of how drug trials are conducted would exclude that method.
> The trial involved about 5,300 women and female adolescents ages 16 to 25 in South Africa and Uganda, some of whom who received Gilead lenacapavir, and others who received older once-daily drugs from Gilead, including Truvada or Descovy.
Not to mention a superficial understanding of how drug trials are conducted would exclude that method.